Skip to main content
Top
Published in: Annals of Surgical Oncology 1/2018

01-01-2018 | Pancreatic Tumors

Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease

Authors: Alexandra G. Lopez-Aguiar, MD, Cecilia G. Ethun, MD, Lauren M. Postlewait, MD, Kristen Zhelnin, MD, Alyssa Krasinskas, MD, Bassel F. El-Rayes, MD, Maria C. Russell, MD, Juan M. Sarmiento, MD, David A. Kooby, MD, Charles A. Staley, MD, Shishir K. Maithel, MD, Kenneth Cardona, MD, FACS

Published in: Annals of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

The Ki-67 index is an established prognostic marker for recurrence after resection of pancreatic neuroendocrine tumors (PanNETs) that groups tumors into three categories: low grade (< 3%), intermediate grade (3–20%), and high grade (> 20%). Given that the majority of resected PanNETs have a Ki-67 less than 3%, this study aimed to stratify this group further to predict disease recurrence more accurately.

Methods

The Ki-67 index was pathologically re-reviewed and scored by a pathologist blinded to all other clinicopathologic variables using tissue microarray blocks made in triplicate. All patients who underwent curative-intent resection of non-metastatic PanNETs at a single institution from 2000 to 2013 were included in the study. The primary outcome was recurrence-free survival (RFS).

Results

Of 113 patients with well-differentiated PanNETs resected, 83 had tissue available for pathologic re-review. The Ki-67 index was lower than 3% for 72 tumors (87%) and between 3 and 20% for 11 tumors (13%). Considering only Ki-67 less than 3%, the tumors were further stratified by Ki-67 into three groups: group A (< 1%, n = 43), group B (1–1.99%, n = 23), and group C (2–2.99%, n = 6). Compared with group A, groups B and C more frequently had advanced T stage (T3: 44% and 67% vs 12%; p = 0.003) and lymphovascular invasion (50% and 83% vs 23%; p = 0.007). Groups B and C had similar 1- and 3-year RFS, both less than group A. After combining groups B and C, a Ki-67 of 1–2.99% was associated with decreased RFS compared with group A (< 1%). This persisted in the multivariable analysis (hazard ratio [HR] 8.6; 95% confidence interval [CI] 1.0–70.7; p = 0.045), with control used for tumor size, margin-positivity, lymph node involvement, and advanced T stage.

Conclusions

PanNETs with a Ki-67 of 1–2.99% exhibit distinct biologic behavior and earlier disease recurrence than those with a Ki-67 lower than 1%. This new stratification scheme, if externally validated, should be incorporated into future grading systems to guide both surveillance protocols and treatment strategies.
Literature
1.
go back to reference Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41:1332–43.CrossRefPubMed Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41:1332–43.CrossRefPubMed
2.
go back to reference Shanahan MA, Salem A, Fisher A, et al. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. J Surg Res. 2016;201:38–43.CrossRefPubMed Shanahan MA, Salem A, Fisher A, et al. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. J Surg Res. 2016;201:38–43.CrossRefPubMed
3.
go back to reference Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scand J Gastroenterol. 2014;49:734–41.CrossRefPubMed Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scand J Gastroenterol. 2014;49:734–41.CrossRefPubMed
4.
go back to reference Dickson PV, Behrman SW. Management of pancreatic neuroendocrine tumors. Surg Clin North Am. 2013;93:675–91.CrossRefPubMed Dickson PV, Behrman SW. Management of pancreatic neuroendocrine tumors. Surg Clin North Am. 2013;93:675–91.CrossRefPubMed
5.
go back to reference Li J, Lin JP, Shi LH, et al. How reliable is the Ki-67 cytological index in grading pancreatic neuroendocrine tumors? A meta-analysis. J Dig Dis. 2016;17:95–103.CrossRefPubMed Li J, Lin JP, Shi LH, et al. How reliable is the Ki-67 cytological index in grading pancreatic neuroendocrine tumors? A meta-analysis. J Dig Dis. 2016;17:95–103.CrossRefPubMed
6.
go back to reference Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909–18.CrossRefPubMed Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909–18.CrossRefPubMed
7.
go back to reference Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. International Agency for Research on Cancer Lyon, 2010. Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. International Agency for Research on Cancer Lyon, 2010.
8.
go back to reference Basturk O, Tang L, Hruban RH, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38:437–47.CrossRefPubMedPubMedCentral Basturk O, Tang L, Hruban RH, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38:437–47.CrossRefPubMedPubMedCentral
9.
go back to reference Lowe K, Khithani A, Liu E, et al. Ki-67 labeling: a more sensitive indicator of malignant phenotype than mitotic count or tumor size? J Surg Oncol. 2012;106:724–7.CrossRefPubMed Lowe K, Khithani A, Liu E, et al. Ki-67 labeling: a more sensitive indicator of malignant phenotype than mitotic count or tumor size? J Surg Oncol. 2012;106:724–7.CrossRefPubMed
10.
go back to reference Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol. 2008;19:282–8.CrossRefPubMed Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol. 2008;19:282–8.CrossRefPubMed
12.
go back to reference Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 2012;13:24–34.CrossRefPubMed Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 2012;13:24–34.CrossRefPubMed
13.
go back to reference Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256:321–5.CrossRefPubMed Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256:321–5.CrossRefPubMed
14.
go back to reference Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis, and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.CrossRefPubMedPubMedCentral Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis, and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.CrossRefPubMedPubMedCentral
15.
go back to reference Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed
16.
go back to reference Salama A, Badawy O, Mokhtar N. Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience. J Cancer Res Clin Oncol. 2014;140:653–61.CrossRefPubMed Salama A, Badawy O, Mokhtar N. Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience. J Cancer Res Clin Oncol. 2014;140:653–61.CrossRefPubMed
17.
go back to reference Liu TC, Hamilton N, Hawkins W, Gao F, Cao D. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2013;37:853–9.CrossRefPubMedPubMedCentral Liu TC, Hamilton N, Hawkins W, Gao F, Cao D. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2013;37:853–9.CrossRefPubMedPubMedCentral
18.
go back to reference Nadler A, Cukier M, Rowsell C, et al. Ki-67 is a reliable pathological grading marker for neuroendocrine tumors. Virchows Arch. 2013;462:501–5.CrossRefPubMed Nadler A, Cukier M, Rowsell C, et al. Ki-67 is a reliable pathological grading marker for neuroendocrine tumors. Virchows Arch. 2013;462:501–5.CrossRefPubMed
19.
go back to reference Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. 2014;38:1353–61.CrossRefPubMed Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. 2014;38:1353–61.CrossRefPubMed
20.
go back to reference McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;37:1671–7.CrossRefPubMedPubMedCentral McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;37:1671–7.CrossRefPubMedPubMedCentral
21.
go back to reference Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–77.CrossRefPubMedPubMedCentral Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–77.CrossRefPubMedPubMedCentral
22.
go back to reference Hamilton NA, Liu TC, Cavatiao A, et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012;152:107–13.CrossRefPubMedPubMedCentral Hamilton NA, Liu TC, Cavatiao A, et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012;152:107–13.CrossRefPubMedPubMedCentral
23.
go back to reference Goodell PP, Krasinskas AM, Davison JM, Hartman DJ. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. Am J Clin Pathol. 2012;137:576–82.CrossRefPubMed Goodell PP, Krasinskas AM, Davison JM, Hartman DJ. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors. Am J Clin Pathol. 2012;137:576–82.CrossRefPubMed
24.
go back to reference Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7.CrossRefPubMed Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7.CrossRefPubMed
25.
go back to reference Tang IP, Singh S, Krishnan G, Looi LM. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses: a rare case. J Laryngol Otol. 2012;126:1284–6.CrossRefPubMed Tang IP, Singh S, Krishnan G, Looi LM. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses: a rare case. J Laryngol Otol. 2012;126:1284–6.CrossRefPubMed
Metadata
Title
Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease
Authors
Alexandra G. Lopez-Aguiar, MD
Cecilia G. Ethun, MD
Lauren M. Postlewait, MD
Kristen Zhelnin, MD
Alyssa Krasinskas, MD
Bassel F. El-Rayes, MD
Maria C. Russell, MD
Juan M. Sarmiento, MD
David A. Kooby, MD
Charles A. Staley, MD
Shishir K. Maithel, MD
Kenneth Cardona, MD, FACS
Publication date
01-01-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6140-8

Other articles of this Issue 1/2018

Annals of Surgical Oncology 1/2018 Go to the issue